CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.9735
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.0830
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Exagen Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.9735
Open* 1.9635
1-Year Change* -26.08%
Day's Range* 1.9435 - 1.9835
52 wk Range 1.33-3.92
Average Volume (10 days) 50.26K
Average Volume (3 months) 1.09M
Market Cap 34.88M
P/E Ratio -100.00K
Shares Outstanding 16.93M
Revenue 51.62M
EPS -1.86
Dividend (Yield %) N/A
Beta 1.22
Next Earnings Date Mar 18, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 1.9735 0.0300 1.54% 1.9435 1.9835 1.9435
Feb 22, 2024 1.9735 0.0200 1.02% 1.9535 1.9935 1.9435
Feb 21, 2024 2.0035 0.0100 0.50% 1.9935 2.0535 1.9435
Feb 20, 2024 2.0535 0.0000 0.00% 2.0535 2.1135 1.9735
Feb 16, 2024 2.0635 -0.0300 -1.43% 2.0935 2.1235 2.0635
Feb 15, 2024 2.0935 0.0300 1.45% 2.0635 2.1035 2.0235
Feb 14, 2024 2.0735 0.0800 4.01% 1.9935 2.0835 1.9435
Feb 13, 2024 2.0635 0.0300 1.48% 2.0335 2.0835 1.9535
Feb 12, 2024 2.0935 0.0800 3.97% 2.0135 2.1135 1.9835
Feb 9, 2024 2.0335 0.1300 6.83% 1.9035 2.0435 1.9035
Feb 8, 2024 1.9935 0.0800 4.18% 1.9135 2.0235 1.9135
Feb 7, 2024 1.9535 0.0400 2.09% 1.9135 1.9835 1.8635
Feb 6, 2024 2.0035 0.0500 2.56% 1.9535 2.0335 1.8835
Feb 5, 2024 1.9435 -0.0700 -3.48% 2.0135 2.0135 1.8735
Feb 2, 2024 2.0635 0.0500 2.48% 2.0135 2.0735 1.9935
Feb 1, 2024 2.0935 0.1000 5.02% 1.9935 2.1935 1.9935
Jan 31, 2024 2.1335 -0.0700 -3.18% 2.2035 2.2735 2.1135
Jan 30, 2024 2.2835 -0.0200 -0.87% 2.3035 2.3335 2.2235
Jan 29, 2024 2.2735 0.3000 15.20% 1.9735 2.3235 1.9735
Jan 26, 2024 1.8935 0.1000 5.58% 1.7935 1.9135 1.7435

Exagen Inc. Events

Time (UTC) Country Event
Monday, March 18, 2024

Time (UTC)

20:00

Country

US

Event

Q4 2023 Exagen Inc Earnings Release
Q4 2023 Exagen Inc Earnings Release

Forecast

-

Previous

-
Monday, May 13, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Exagen Inc Earnings Release
Q1 2024 Exagen Inc Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

15:00

Country

US

Event

Exagen Inc Annual Shareholders Meeting
Exagen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 45.563 48.299 41.975 40.387 32.44
Revenue 45.563 48.299 41.975 40.387 32.44
Cost of Revenue, Total 24.214 20.588 16.559 18.808 15.379
Gross Profit 21.349 27.711 25.416 21.579 17.061
Total Operating Expense 91.614 72.366 57.16 49.686 37.32
Selling/General/Admin. Expenses, Total 52.018 44.541 37.033 28.702 19.675
Research & Development 9.876 7.237 3.568 2.176 2.125
Depreciation / Amortization 0 0.141
Interest Expense (Income) - Net Operating 0 0
Unusual Expense (Income) 5.506 0 0
Operating Income -46.051 -24.067 -15.185 -9.299 -4.88
Interest Income (Expense), Net Non-Operating -2.448 -2.625 -2.565 -3.224 -3.186
Other, Net 0.83 0.016 0.984 0.51 0.112
Net Income Before Taxes -47.669 -26.676 -16.766 -12.013 -7.954
Net Income After Taxes -47.387 -26.851 -16.687 -12.038 -8.012
Net Income Before Extra. Items -47.387 -26.851 -16.687 -12.038 -8.012
Net Income -47.387 -26.851 -16.687 -12.038 -8.012
Total Adjustments to Net Income 0 -18.241 -10.47
Income Available to Common Excl. Extra. Items -47.387 -26.851 -16.687 -30.279 -18.482
Income Available to Common Incl. Extra. Items -47.387 -26.851 -16.687 -30.279 -18.482
Dilution Adjustment
Diluted Net Income -47.387 -26.851 -16.687 -30.279 -18.482
Diluted Weighted Average Shares 17.0823 15.9723 12.6328 12.561 11.5779
Diluted EPS Excluding Extraordinary Items -2.77403 -1.6811 -1.32093 -2.41056 -1.59631
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -2.56452 -1.6811 -1.32093 -2.41056 -1.59631
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 14.137 11.23 12.837 14.726 7.606
Revenue 14.137 11.23 12.837 14.726 7.606
Cost of Revenue, Total 5.836 5.926 6.309 6.01 6.078
Gross Profit 8.301 5.304 6.528 8.716 1.528
Total Operating Expense 19.052 18.936 27.328 22.543 21.67
Selling/General/Admin. Expenses, Total 11.953 11.884 12.812 14.151 12.903
Research & Development 1.263 1.126 2.701 2.382 2.689
Operating Income -4.915 -7.706 -14.491 -7.817 -14.064
Interest Income (Expense), Net Non-Operating -0.574 -0.638 -0.626 -0.618 -0.606
Other, Net 0.476 0.656 0.481 0.339 0.005
Net Income Before Taxes -5.013 -7.688 -14.636 -8.096 -14.665
Net Income After Taxes -5.013 -7.688 -14.354 -8.096 -14.665
Net Income Before Extra. Items -5.013 -7.688 -14.354 -8.096 -14.665
Net Income -5.013 -7.688 -14.354 -8.096 -14.665
Income Available to Common Excl. Extra. Items -5.013 -7.688 -14.354 -8.096 -14.665
Income Available to Common Incl. Extra. Items -5.013 -7.688 -14.354 -8.096 -14.665
Diluted Net Income -5.013 -7.688 -14.354 -8.096 -14.665
Diluted Weighted Average Shares 17.6555 17.5268 17.1955 17.081 17.0585
Diluted EPS Excluding Extraordinary Items -0.28393 -0.43864 -0.83475 -0.47398 -0.85969
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.28393 -0.43864 -0.62662 -0.47398 -0.85969
Unusual Expense (Income) 5.506
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 72.611 112.734 70.517 81.25 21.312
Cash and Short Term Investments 62.391 99.442 57.448 72.084 13.164
Cash & Equivalents 62.391 99.442 57.448 72.084 13.164
Total Receivables, Net 6.077 9.654 8.91 5.715 5.952
Accounts Receivable - Trade, Net 6.077 9.654 8.91 5.715 5.952
Prepaid Expenses 4.143 3.638 4.159 3.451 2.196
Total Assets 86.221 123.445 78.375 88.31 28.887
Property/Plant/Equipment, Total - Net 13.082 4.772 2.102 1.38 1.566
Property/Plant/Equipment, Total - Gross 18.206 8.656
Accumulated Depreciation, Total -5.124 -3.884
Goodwill, Net 0 5.506 5.506 5.506 5.506
Intangibles, Net 0
Other Long Term Assets, Total 0.528 0.433 0.25 0.174 0.503
Total Current Liabilities 9.623 9.318 8.771 5.895 8.952
Accounts Payable 3.046 2.492 3.014 1.476 1.279
Accrued Expenses 5.242 6.239 5.449 4.419 3.923
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.89 0.587 0.308
Other Current Liabilities, Total 0.445 0 3.75
Total Liabilities 43.761 38.509 36.536 32.651 35.621
Total Long Term Debt 29.626 27.478 26.659 25.854 24.617
Other Liabilities, Total 4.512 1.407 0.948 0.638 1.807
Total Equity 42.46 84.936 41.839 55.659 -6.734
Redeemable Preferred Stock 0 105.232
Common Stock 0.017 0.016 0.013 0.013 0.012
Additional Paid-In Capital 297.97 293.06 223.115 220.248 40.586
Retained Earnings (Accumulated Deficit) -255.527 -208.14 -181.289 -164.602 -152.564
Total Liabilities & Shareholders’ Equity 86.221 123.445 78.375 88.31 28.887
Total Common Shares Outstanding 16.55 16.165 12.6523 12.561 11.5779
Long Term Debt 28.778 27.478 26.659 25.854 24.617
Deferred Income Tax 0 0.306 0.158 0.264 0.245
Preferred Stock - Non Redeemable, Net 0 0 0
Capital Lease Obligations 0.848
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 48.908 51.271 65.716 72.611 82.06
Cash and Short Term Investments 28.448 31.466 52.184 62.391 68.704
Cash & Equivalents 28.448 31.466 52.184 62.391 68.704
Total Receivables, Net 17.044 16.235 9.303 6.077 10.639
Accounts Receivable - Trade, Net 17.044 16.235 9.303 6.077 10.639
Prepaid Expenses 3.416 3.57 4.229 4.143 2.717
Total Assets 60.928 64.178 79.234 86.221 101.597
Property/Plant/Equipment, Total - Net 11.382 12.287 12.915 13.082 13.445
Property/Plant/Equipment, Total - Gross 18.45 18.585 18.206 18.352
Accumulated Depreciation, Total -6.163 -5.67 -5.124 -4.907
Goodwill, Net 0 5.506
Other Long Term Assets, Total 0.638 0.62 0.603 0.528 0.586
Total Current Liabilities 10.119 8.603 9.268 9.623 11.332
Accounts Payable 1.657 1.309 1.878 3.046 3.669
Accrued Expenses 8.201 6.188 6.041 5.242 6.488
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.261 0.852 0.904 0.89 0.73
Total Liabilities 33.424 32.276 43.297 43.761 45.411
Total Long Term Debt 19.193 19.153 29.092 29.626 28.982
Long Term Debt 19.193 19.153 29.092 28.778 28.008
Deferred Income Tax 0 0.306
Other Liabilities, Total 4.112 4.52 4.937 4.512 4.791
Total Equity 27.504 31.902 35.937 42.46 56.186
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.017 0.017 0.017 0.017 0.016
Additional Paid-In Capital 301.13 300.113 299.135 297.97 297.343
Retained Earnings (Accumulated Deficit) -273.643 -268.228 -263.215 -255.527 -241.173
Total Liabilities & Shareholders’ Equity 60.928 64.178 79.234 86.221 101.597
Total Common Shares Outstanding 16.9319 16.8582 16.827 16.55 16.3055
Capital Lease Obligations 0.848 0.974
Other Current Liabilities, Total 0.254 0.445 0.445 0.445
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -47.387 -26.851 -16.687 -12.038 -8.012
Cash From Operating Activities -32.144 -20.269 -14.084 -9.711 -9.301
Cash From Operating Activities 1.557 0.948 0.546 0.591 0.731
Deferred Taxes -0.306 0.148 -0.106 0 0.031
Non-Cash Items 12.322 5.547 3.499 1.562 1.54
Cash Interest Paid 1.732 1.815 1.758 2.288 1.73
Changes in Working Capital 1.67 -0.061 -1.336 0.174 -3.591
Cash From Investing Activities -4.318 -2.42 -0.455 -0.103 -0.199
Capital Expenditures -4.318 -2.42 -0.455 -0.403 -0.199
Other Investing Cash Flow Items, Total 0 0.3 0
Cash From Financing Activities -0.489 64.683 -0.097 68.734 11.423
Financing Cash Flow Items -0.239 -4.447 -0.021 0
Issuance (Retirement) of Stock, Net 0.446 69.655 0.173 68.872 6.466
Issuance (Retirement) of Debt, Net -0.696 -0.525 -0.249 -0.138 4.957
Net Change in Cash -36.951 41.994 -14.636 58.92 1.923
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -7.688 -47.387 -33.033 -24.937 -10.272
Cash From Operating Activities -9.749 -32.144 -26.41 -19.728 -8.574
Cash From Operating Activities 0.553 1.557 1.037 0.597 0.283
Deferred Taxes -0.306
Non-Cash Items 1.454 12.322 5.423 3.68 1.768
Cash Interest Paid 0.449 1.732 1.297 0.86 0.424
Changes in Working Capital -4.068 1.67 0.163 0.932 -0.353
Cash From Investing Activities -0.396 -4.318 -3.912 -3.033 -1.087
Capital Expenditures -0.396 -4.318 -3.912 -3.033 -1.087
Cash From Financing Activities -0.062 -0.489 -0.316 -0.294 -0.03
Financing Cash Flow Items 0 -0.239 -0.224 -0.222 -0.115
Issuance (Retirement) of Stock, Net 0.179 0.446 0.385 0.231 0.231
Issuance (Retirement) of Debt, Net -0.241 -0.696 -0.477 -0.303 -0.146
Net Change in Cash -10.207 -36.951 -30.638 -23.055 -9.691
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
NMSIC Co-Investment Fund, L.P Corporation 13.6959 2308958 0 2022-12-31
H.I.G. Capital, LLC Private Equity 10.0615 1696252 0 2023-04-18 LOW
Tullis Health Investors Venture Capital 8.9904 1515672 0 2022-12-31
RTW Investments L.P. Investment Advisor/Hedge Fund 8.8526 1492432 101248 2023-06-30 LOW
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund 6.2244 1049352 12278 2023-06-30 HIGH
Wasatch Global Investors Inc Investment Advisor/Hedge Fund 5.9366 1000844 283 2023-06-30 LOW
Lytton (Laurence W) Individual Investor 5.1675 871181 37876 2022-12-31 HIGH
Cowen & Co., LLC Research Firm 4.9967 842376 -101176 2023-06-30 MED
Silvercrest Asset Management Group LLC Investment Advisor/Hedge Fund 3.2454 547133 44518 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9121 490944 0 2023-06-30 LOW
Morgan Stanley & Co. LLC Research Firm 2.8531 481000 -72 2023-06-30 MED
Rocca (Fortunato Ron) Individual Investor 1.6464 277562 269384 2023-04-18 HIGH
Perkins Capital Management, Inc. Investment Advisor 1.5654 263905 4000 2023-06-30 LOW
Florida State Board of Administration Pension Fund 0.9084 153143 43988 2022-09-30 LOW
UBS Financial Services, Inc. Investment Advisor 0.7761 130833 0 2023-06-30 LOW
Nantahala Capital Management, LLC Hedge Fund 0.723 121894 -10719 2023-06-30 MED
Zack (Debra Jeske) Individual Investor 0.6496 109519 103385 2023-04-18
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4449 75000 0 2023-06-30 LOW
Penbrook Management, LLC Investment Advisor 0.4354 73410 -600 2023-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.4025 67861 2604 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Exagen Inc. Company profile

About Exagen Inc

Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. The Company's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases ( CTD) and Systemic lupus erythematosus (SLE). Its other diagnostic testing includes AVISE Lupus and AVISE antiphospholipid syndrome (APS). Its Prognosis tests include AVISE systemic lupus erythematosus (SLE) Prognostic, AVISE Anti- carbamylated proteins (CarP) and AVISE Platelet-bound C4d (PC4d). Its monitoring tests include AVISE SLE Monitor, AVISE methotrexate (MTX) and AVISE hydroxychloroquine (HCQ).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Exagen Inc revenues increased 22% to $35.6M. Net loss increased 50% to $19.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, general & administrative exp increase from $200K to $28.5M (expense), Other income / (expense), net decrease of 100% to $1K (income).

Industry: Healthcare Facilities & Services (NEC)

1261 Liberty Way Ste C
VISTA
CALIFORNIA 92081-8356
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.54 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

51,488.20 Price
-0.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,031.07 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

76.09 Price
-0.590% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading